Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPO906 in advanced colorectal cancer
NCT00035087Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2002
- Primary completion
- Mar 2003
- Modality
- Covalent Small Molecules, RNA-Targeting Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patupilone in colorectal cancer (CRC), sponsored by Novartis. Primary endpoint: Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST). Started May 2002; status: completed.
02
Drugs
patupilone
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00035087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035087.